The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).
 
Isabella Claudia Glitza
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Leal Therapeutics; Midatech Pharma; Novartis; Sintetica
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
Ida John
No Relationships to Disclose
 
Suzanne Phillips
No Relationships to Disclose
 
Lauren See
No Relationships to Disclose
 
Roland L. Bassett
No Relationships to Disclose
 
Ruitao Lin
No Relationships to Disclose
 
Michelle L. Rohlfs
No Relationships to Disclose
 
Jessie Richard
No Relationships to Disclose
 
Masood Iqbal
No Relationships to Disclose
 
Tarin Hennegan
No Relationships to Disclose
 
Ian E. McCutcheon
No Relationships to Disclose
 
Sherise D. Ferguson
No Relationships to Disclose
 
Golnaz Morad
No Relationships to Disclose
 
Barbara Jane O'Brien
Consulting or Advisory Role - Plus Therapeutics
Research Funding - EMD Serono (Inst); Kintara (Inst)
 
Sudhakar Tummala
No Relationships to Disclose
 
Nandita Guha- Thakurta
No Relationships to Disclose
 
Matthew Debnam
No Relationships to Disclose
 
Hussein A. Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Medicenna; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)
 
Elizabeth M. Burton
No Relationships to Disclose
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Pfizer
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)